Unicycive Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
UNCY Nasdaq 2830 unicycive.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Unicycive Therapeutics, Inc.

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - Jun 30th, 2025 5:05 am
Unicycive Therapeutics, Inc. Announces Reverse Stock Split - Jun 17th, 2025 5:00 am
Retail investors are Unicycive Therapeutics, Inc.'s (NASDAQ:UNCY) biggest owners and were hit after market cap dropped US$28m - Jun 11th, 2025 4:46 am
Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - Jun 10th, 2025 4:00 am
Unicycive Therapeutics to Present at Upcoming Investor Conferences - May 22nd, 2025 5:00 am
Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders - May 21st, 2025 5:00 am
Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update - May 14th, 2025 5:15 am
Analysts Expect Breakeven For Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Before Long - May 7th, 2025 6:16 am
Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis - Apr 10th, 2025 6:00 am
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference - Apr 1st, 2025 5:00 am
Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update - Mar 31st, 2025 5:00 am
Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia - Mar 13th, 2025 5:00 am
Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360 - Feb 20th, 2025 5:00 am
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science - Jan 28th, 2025 5:00 am
Here's Why We're Watching Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Situation - Jan 28th, 2025 4:58 am
Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science - Jan 7th, 2025 5:00 am
Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics - Dec 17th, 2024 5:00 am
Breakeven On The Horizon For Unicycive Therapeutics, Inc. (NASDAQ:UNCY) - Nov 28th, 2024 4:57 am
Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference - Nov 21st, 2024 5:00 am
Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update - Nov 13th, 2024 5:15 am